Results 81 to 90 of about 1,281 (134)

Myoferlin controls mitochondrial structure and metabolism in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness.

, 2018
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, and the third leading cause of cancer related death. Therapeutic options remain very limited and are still based on classical chemotherapies.
Hennequière, Vincent, LOVINFOSSE, Pierre, Thiry, Marc, Castronovo, Vincenzo, Nokin, Marie-Julie, Herfs, Michael, Brohée, Laura, Rademaker, Gilles, Bellahcene, Akeila, Peulen, Olivier   +9 more
core  

No effect of dysferlin or myoferlin knockdown on VEGFR-2 and caveolin-1 expression.

, 2012
16HBE cells were transfected with oligofectamine transfection reagent (TF con), scrambled siRNA (S), dysferlin or myoferlin siRNA at 50 nM, 75 nM and 100 nM for 72 h.
Tillie-Louise Hackett (92016), Furquan Shaheen (152799), Pascal Bernatchez (152801), Cleo Leung (152795)   +3 more
core   +1 more source

L'inhibition pharmacologique de la myoferline induit une mort cellulaire de type ferroptotique et augmente la vulnérabilité du cancer du pancréas à la radiothérapie

In 2020, globally, the total number of new pancreatic cancer (PDAC) cases was around 500,000, and the total number of deaths from pancreatic cancer was 470,000. This context led our Laboratory to highlight new PDAC biomarkers.
Boumahd, Yasmine
core  

Role of myoferlin in mitochondrial dynamics and metabolic fitness of PDAC

, 2019
Our data strongly suggest that myoferlin interacts with MFN. Indeed, if myoferlin is a part of the mitochondrial fusion machinery, its silencing together with an unopposed fission would lead to mitochondrial fragmentation.Role of myoferlin in ...
Wissocq, Tom, Castronovo, Vincenzo, Rademaker, Gilles, Bellahcene, Akeila, Peulen, Olivier, Anania, Sandy   +5 more
core  

Morphology change following myoferlin depletion in MDA-MB-231 cells.

, 2012
Immunofluorescence micrographs showing the morphology of MDA-MB-231 wild type (WT), lentiviral transduction control (LTV-ctrl), and myoferlin knockdown (MYOF-KD) stable cell lines in culture.
Samir Ghadiali (155520), Douglas A. Kniss (155523), William E. Ackerman IV (155503), Leonithas I. Volakis (155515), Ruth Li (155497), Cosmin Mihai (155508)   +5 more
core   +1 more source

Knockdown of myoferlin but not dysferlin alters cell morphology and cell detachment.

, 2012
Phase contrast images captured at 10× magnification of 16HBE cells treated with control media, transfection control, scrambled siRNA, and (A) dysferlin siRNA or (B) myoferlin siRNA at 50 nM, 75 nM and 100 nM for 72 h.
Tillie-Louise Hackett (92016), Furquan Shaheen (152799), Pascal Bernatchez (152801), Cleo Leung (152795)   +3 more
core   +1 more source

Role of myoferlin in mitochondrial dynamics and metabolic fitness of pancreas cancer

, 2019
Pancreatic cancer is the 7th most common cause of cancer mortality in the world. It is predicted to become the second leading cause of cancer-related death in 2030. Myoferlin is a 230 kDa protein overexpressed in pancreatic cancer.
Wissocq, Tom, Castronovo, Vincenzo, Rademaker, Gilles, Bellahcene, Akeila, Peulen, Olivier, Anania, Sandy   +5 more
core   +1 more source

Role of myoferlin in mitochondrial dynamics and metabolic fitness of Pancreatic Ductal Adenocarcinoma

, 2019
Pancreatic cancer is the 7th most common cause of cancer mortality in the world. It is predicted to become the 2nd leading cause of cancer-related death in 2030.
Castronovo, Vincenzo, Rademaker, Gilles, Bellahcene, Akeila, Peulen, Olivier, Anania, Sandy   +4 more
core  

Myoferlin at the crossroad of vesicle trafficking and mitochondrial function: implications for pancreatic cancer progression and stromal reprogramming. [PDF]

Biochem Soc Trans
Peiffer R, Laverdeur E, Genbauffe A, Bellahcène A, Rademaker G, Peulen O.   +5 more
europepmc   +1 more source

Tetraspanin CD82 Associates with Trafficking Vesicle in Muscle Cells and Binds to Dysferlin and Myoferlin. [PDF]

Adv Biol (Weinh), 2023
Fontelonga T, Hall AJ, Brown JL, Jung YL, Alexander MS, Dominov JA, Mouly V, Vieira N, Zatz M, Vainzof M, Gussoni E.   +10 more
europepmc   +1 more source